Nolvadex (Tamoxifen) an Antioestrogen of Potential Use in the Management of Carcinoma of the Prostate

  • M. R. G. Robinson
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


Well-differentiated prostatic cancer cells, like normal prostatic cells, remain for a time, androgen-dependent. Oestrogens in sufficient dosage reduce circulating androgens, and this has been the rationale for conventional oestrogen therapy. At least 3 mg. daily of Stilboestrol, in divided doses, are needed to suppress plasma testosterone levels throughout 24 hours (1,2), but clinically 1 mg. per day is as effective in controlling the disease (3). This therapeutic evidence for an additional direct action of oestrogens upon the prostate is supported by the classical animal experiments of Huggins and Clark in 1940 (4) and by the tissue culture studies of Earnsworth (5).


Plasma Testosterone Level Tissue Culture Study Hormone Dependent Breast Cancer Secondary Rise Objective Partial Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M.R.G. Robinson and B.G. Thomas, Effect of Hormone Therapy and Plasma Testosterone Levels in Prostatic Cancer, B.M.J. 4:391 (1971).CrossRefGoogle Scholar
  2. 2.
    R.J. Shearer, W.F. Hendry, I.F. Sommeryille and J.D. Fergusson, Plasma Testosterone: An Accurate Monitor of Hormone Treatment in Prostatic Cancer, Brit. J. Urol. 45:668 (1973).PubMedCrossRefGoogle Scholar
  3. 3.
    D.P. Byar, The Veterans Administrators Co-operative Urological Group’s Studies of Cancer of the Prostate: A Preliminary Report, Cancer 32:1126 (1973).PubMedCrossRefGoogle Scholar
  4. 4.
    C. Huggins and P.J. Clark, The Effects of Castration and Estrogen Injections on the Normal and Hyperplastic Prostate Gland of Dogs, J. Exp. Med. 72:747 (1941).CrossRefGoogle Scholar
  5. 5.
    W.E. Farnsworth, The Normal Prostate and Its Endocrine Control, in “The Third Tenovus Workshop — Some Aspects of the Aetiology and Biochemistry of Prostatic Cancer”, K. Griffith and C.G. Pierrpoint (eds), Alpha Omega Ltd., Cardiff (1970) p. 3.Google Scholar
  6. 6.
    E.F. Hawkins et al, Steroid Receptors in the Human Prostate, Steroids, 26:458 (1975).PubMedCrossRefGoogle Scholar
  7. 7.
    J.R. Murphy, R.C. Emmott, L.L. Hicks and P.C. Walsh, Estrogen Receptors in the Human Prostate, Seminal Vesicle, Testes and Genital Skin: A Marker for Estrogen — Responsive Tissues? J. Clin. Endocrinol. and Metab. 50:938 (1980).CrossRefGoogle Scholar
  8. 8.
    T.T. Kiang and B.J. Kennedy, Tamoxifen (Antioestrogen) Therapy in Advanced Breast Cancer, Ann. Intern. Med. 87:687 (1977).PubMedCrossRefGoogle Scholar
  9. 9.
    S. Legha and F.M. Muggia, Antiestrogens in the Treatment of Cancer, Ann. Intern. Med. 84:751 (1976).PubMedCrossRefGoogle Scholar
  10. 10.
    R.C. Heel, R.C. Brogden, T.M. Speight and G.S. Avery, Tamoxifen; A Review of its Pharmacological Properties and Their Therapeutic Use in the Treatment of Breast Cancer, Drugs. 16:1 (1968).CrossRefGoogle Scholar
  11. 11.
    M.M. Ip, R.J. Milholland and F. Rosen, Functionality of Estrogen Receptor and Tamoxifen Treatment of R3327 Dunning Rat Prostate Adenocarcinoma, Cancer Res. 40:2188 (1980).PubMedGoogle Scholar
  12. 12.
    F. Comhaire, Hormone Effect of an Antioestrogen, Tamoxifen, in Normal and Oligospermic Men, Fertility and Sterility, 29:320 (1978).PubMedGoogle Scholar
  13. 13.
    F.K. Habib, G. Rafat, M.R.G. Robinson and S.R. Stitch, Effects of Tamoxifen on the Binding and Metabolism of Testosterone by Human Prostatic Tissue and Plasma in Vitro, J. Endocrinol. 83:369 (1979).PubMedCrossRefGoogle Scholar
  14. 14.
    J.L. Williams, Personal Communication (1980).Google Scholar
  15. 15.
    L.R. Morgan, L.E. Posey and J. Lanasa, Therapeutic Use of Nolvadex (Tamoxifen ICI 46, 4741) in Advanced Prostatic Cancer, Proc. of 12. Int. Cancer Congress, Beunos Aires, 5–11 October 1978, W51 page 111, Abstract 17.Google Scholar
  16. 16.
    J.H. Glick, A. Wein, K. Padavic, W. Negendamk, D. Harris and H. Brodovsky, Tamoxifen in Refractory Metastatic Carcinoma of the Prostate, Cancer Treat. Rep. 64:813 (1980).PubMedGoogle Scholar
  17. 17.
    W.B. Pratt and R.W. Ruddon, “The Anticancer Drugs, Oxford University Press, (1979) p. 212.Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • M. R. G. Robinson
    • 1
  1. 1.The General InfirmaryPontefractUK

Personalised recommendations